Investors Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of some unusual options trading on Friday. Stock investors acquired 62,593 call options on the company. This represents an increase of approximately 139% compared to the average volume of 26,225 call options.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Softbank Group CORP. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $99,152,000. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after buying an additional 9,737,196 shares during the last quarter. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the period. Finally, Norges Bank acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at $23,429,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the topic of several research analyst reports. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley lowered their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.20.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $5.76 on Friday. The company has a 50 day moving average price of $6.83 and a two-hundred day moving average price of $6.84. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The stock has a market capitalization of $2.32 billion, a PE ratio of -3.76 and a beta of 1.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the company posted ($0.42) earnings per share. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. As a group, equities analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.